{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-24-000004","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.434048+00:00","generated_at":"2026-06-06T20:15:03.869667+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"JNJ Q4 2023 revenue $21.4B (+7.3% YoY), adjusted EPS $2.29 (+11.7%)","bullets":["Q4 sales $21,395M (+7.3% YoY); FY 2023 sales $85,159M (+6.5% YoY).","Q4 net earnings from continuing ops $4,132M (diluted EPS $1.70, +39.3% YoY).","Adjusted Q4 net earnings from continuing ops $5,562M (diluted EPS $2.29, +11.7% YoY).","Innovative Medicine ex-COVID vaccine grew 9.7% in Q4; MedTech grew 13.3%.","FY 2023 operational sales growth 7.4% total, 8.0% ex-COVID vaccine."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-24-000004","json":"https://secwatch.observer/filing/0000200406-24-000004.json","markdown":"https://secwatch.observer/filing/0000200406-24-000004.md","text":"https://secwatch.observer/filing/0000200406-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040624000004/0000200406-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040624000004/jnj-20240123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:15:03.869667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}